Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Emergent BioSolutions (NYSE: EBS) announced that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14, 2025 after 19 years of service.
Dr. Sullivan joined the board in 2006 and most recently served as chair of the compensation committee and as a member of the nominating and corporate governance committee. The company noted his experience in healthcare, government and biotechnology and cited his role guiding decisions during Emergent’s multi-year transformation. Dr. Sullivan previously served as president of Morehouse School of Medicine and as Secretary of the Department of Health and Human Services.
Emergent BioSolutions (NYSE: EBS) ha annunciato che Dr. Louis W. Sullivan si ritirerà dal Consiglio di Amministrazione dell'azienda con effetto dal 14 novembre 2025 dopo 19 anni di servizio.
Il Dr. Sullivan è entrato nel consiglio nel 2006 e di recente ha ricoperto la carica di presidente della commissione compensi e come membro della commissione nominante e di governance aziendale. L'azienda ha evidenziato la sua esperienza nel settore sanitario, nel governo e nelle biotecnologie e ha citato il suo ruolo nel guidare decisioni durante la trasformazione pluriennale di Emergent. Il Dr. Sullivan ha precedentemente ricoperto il ruolo di presidente della Morehouse School of Medicine e di Segretario del Dipartimento della Salute e dei Servizi Umani.
Emergent BioSolutions (NYSE: EBS) anunció que el Dr. Louis W. Sullivan se retirará de la Junta Directiva de la empresa con efecto el 14 de noviembre de 2025 tras 19 años de servicio.
El Dr. Sullivan se unió a la junta en 2006 y desempeñó recientemente el cargo de presidente del comité de compensación y como miembro del comité de nominación y gobierno corporativo. La empresa señaló su experiencia en atención médica, gobierno y biotecnología y citó su papel orientando decisiones durante la transformación de varios años de Emergent. El Dr. Sullivan se desempeñó previamente como presidente de Morehouse School of Medicine y como Secretario del Departamento de Salud y Servicios Humanos.
Emergent BioSolutions (NYSE: EBS) 는 Louis W. Sullivan 박사가 2025년 11월 14일 부로 회사의 이사회에서 은퇴한다고 발표했으며 19년 간의 근속을 마칩니다.
Sullivan 박사는 2006년에 이사회에 합류했고 최근에는 보상위원회 의장과 지명 및 기업 거버넌스 위원의 직을 맡아 왔습니다. 회사는 그의 의료, 정부 및 생명공학 분야의 경험과 Emergent의 수년간의 전환 과정에서 의사결정을 이끄는 그의 역할을 언급했습니다. Sullivan 박사는 이전에 Morehouse School of Medicine의 대통령과 보건복지부 장관을 역임했습니다.
Emergent BioSolutions (NYSE: EBS) a annoncé que le docteur Louis W. Sullivan prendra sa retraite du conseil d'administration de l'entreprise à compter du 14 novembre 2025 après 19 années de service.
Le Dr Sullivan a rejoint le conseil en 2006 et a occupé récemment le poste de président de la commission des rémunérations et comme membre de la commission de nomination et de la gouvernance d'entreprise. L'entreprise a souligné son expérience dans les domaines de la santé, du gouvernement et de la biotechnologie et a cité son rôle dans l'orientation des décisions pendant la transformation pluriannuelle d'Emergent. Le Dr Sullivan avait auparavant été président de Morehouse School of Medicine et secrétaire du Department of Health and Human Services.
Emergent BioSolutions (NYSE: EBS) gab bekannt, dass Dr. Louis W. Sullivan mit Wirkung vom 14. November 2025 aus dem Vorstand des Unternehmens zurücktreten wird, nach 19 Jahren im Amt.
Dr. Sullivan trat 2006 in den Vorstand ein und diente zuletzt als Vorsitzender des Vergütungsausschusses sowie als Mitglied des Nominierungs- und Corporate-Governance-Ausschusses. Das Unternehmen hob seine Erfahrungen im Gesundheitswesen, in der Regierung und in der Biotechnologie hervor und nannte seine Rolle bei der Leitung von Entscheidungen während der mehrjährigen Transformation von Emergent. Dr. Sullivan war zuvor Präsident der Morehouse School of Medicine und als Sekretär des Department of Health and Human Services tätig.
Emergent BioSolutions (NYSE: EBS) أعلنت أن الدكتور لويس دبليو. سوليفان سيتقاعد من مجلس إدارة الشركة اعتباراً من 14 نوفمبر 2025 بعد 19 عاماً من الخدمة.
انضم الدكتور سوليفان إلى المجلس في 2006 وشغل مؤخراً منصب رئيس لجنة التعويضات وعضو لجنة الترشيحات والحوكمة المؤسسية. أشارت الشركة إلى خبرته في الرعاية الصحية والحكومة والتكنولوجيا الحيوية وذكرت دوره في توجيه القرارات خلال التحول على مدار سنوات طويلة لشركة Emergent. كان الدكتور Sullivan سابقاً رئيس كلية مورهاوس للطب ووزير الصحة والخدمات الإنسانية.
- None.
- None.
GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the company and its shareholders.
“For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent’s mission to protect and save lives,” said Joe Papa, president and CEO of Emergent. “On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best.”
Dr. Sullivan served on Emergent’s Board of Directors since 2006, and most recently served as chair of the compensation committee and a member of the nominating and corporate governance committee. His independence and experience in healthcare, government and biotechnology helped guide critical decisions through Emergent’s history, including its current multi-year transformation. He served as president of Morehouse School of Medicine from 1981 to 1989 and from 1993 to 2002 and was Secretary of the Department of Health and Human Services from 1989 to 1993.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When does Dr. Louis W. Sullivan retire from the Emergent BioSolutions board (EBS)?
How long did Dr. Louis W. Sullivan serve on Emergent BioSolutions' (EBS) board?
What roles did Dr. Louis W. Sullivan hold on the Emergent BioSolutions (EBS) board?
Will Emergent BioSolutions (EBS) name a replacement for Dr. Sullivan on the board?
What past public service and academic roles does Dr. Louis W. Sullivan have?
Did Emergent BioSolutions (EBS) cite reasons for Dr. Sullivan’s retirement?
